[Translation] An international, multicenter, prospective, open-label, randomized, noncomparative phase II study evaluating lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and in combination with an androgen receptor inhibitor in patients with PSMA PET scan-positive castration-resistant prostate cancer (PSMACare).
评价AAA617单药以及与雄激素受体通路抑制剂(ARPI)联合用药在常规影像学检查(CI;即CT/MRI和骨扫描)显示无转移证据的PSMA阳性去势抵抗性前列腺癌受试者中的疗效和安全性。
[Translation] To evaluate the efficacy and safety of AAA617 alone and in combination with an androgen receptor pathway inhibitor (ARPI) in subjects with PSMA-positive castration-resistant prostate cancer who have no evidence of metastasis on conventional imaging (CI; i.e., CT/MRI and bone scan).